The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

8 OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic ...

Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain, rash ...